Barely Significant
← all excerpts

Role of favipiravir in the treatment of COVID-19.

Int J Infect Dis · 2021 · PMC7831863 · PMID 33130203

Europe PMCDOI
2
hedged sentences
0.0550
closest p · 1.1× alpha
0.0550
boldest claim

The sentences

reached near significancep = 0.055so close (0.05 < p ≤ 0.1)
Multivariable Cox regression showed that favipiravir was significantly (p = 0.026) associated with faster viral clearance, additionally the timing of antiviral therapy reached near significance (p = 0.055).

also in 50 other papers

showed a trendno p-value reported
Latest prospective, randomized, open-label trial of early versus late favipiravir in hospitalized patients with COVID-19 published in a peer-reviewed journal done at 25 hospitals across Japan showed a trend toward better viral clearance on day 6 (66.7% versus 56.1%) with the early treatment group (adjusted hazard ratio [aHR], 1.42 and 95% confidence interval [95% CI], 0.76–2.62).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.